M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 3.66 USD -6.63% Market Closed
Market Cap: 110.6m USD
Have any thoughts about
Myomo Inc?
Write Note

Intrinsic Value

The intrinsic value of one MYO stock under the Base Case scenario is 3.51 USD. Compared to the current market price of 3.66 USD, Myomo Inc is Overvalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MYO Intrinsic Value
3.51 USD
Overvaluation 4%
Intrinsic Value
Price
M
Base Case Scenario

Valuation Backtest
Myomo Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MYO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MYO?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Myomo Inc

Provide an overview of the primary business activities
of Myomo Inc.

What unique competitive advantages
does Myomo Inc hold over its rivals?

What risks and challenges
does Myomo Inc face in the near future?

Has there been any significant insider trading activity
in Myomo Inc recently?

Summarize the latest earnings call
of Myomo Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Myomo Inc.

Provide P/S
for Myomo Inc.

Provide P/E
for Myomo Inc.

Provide P/OCF
for Myomo Inc.

Provide P/FCFE
for Myomo Inc.

Provide P/B
for Myomo Inc.

Provide EV/S
for Myomo Inc.

Provide EV/GP
for Myomo Inc.

Provide EV/EBITDA
for Myomo Inc.

Provide EV/EBIT
for Myomo Inc.

Provide EV/OCF
for Myomo Inc.

Provide EV/FCFF
for Myomo Inc.

Provide EV/IC
for Myomo Inc.

Show me price targets
for Myomo Inc made by professional analysts.

What are the Revenue projections
for Myomo Inc?

How accurate were the past Revenue estimates
for Myomo Inc?

What are the Net Income projections
for Myomo Inc?

How accurate were the past Net Income estimates
for Myomo Inc?

What are the EPS projections
for Myomo Inc?

How accurate were the past EPS estimates
for Myomo Inc?

What are the EBIT projections
for Myomo Inc?

How accurate were the past EBIT estimates
for Myomo Inc?

Compare the revenue forecasts
for Myomo Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Myomo Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Myomo Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Myomo Inc compared to its peers.

Compare the P/E ratios
of Myomo Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Myomo Inc with its peers.

Analyze the financial leverage
of Myomo Inc compared to its main competitors.

Show all profitability ratios
for Myomo Inc.

Provide ROE
for Myomo Inc.

Provide ROA
for Myomo Inc.

Provide ROIC
for Myomo Inc.

Provide ROCE
for Myomo Inc.

Provide Gross Margin
for Myomo Inc.

Provide Operating Margin
for Myomo Inc.

Provide Net Margin
for Myomo Inc.

Provide FCF Margin
for Myomo Inc.

Show all solvency ratios
for Myomo Inc.

Provide D/E Ratio
for Myomo Inc.

Provide D/A Ratio
for Myomo Inc.

Provide Interest Coverage Ratio
for Myomo Inc.

Provide Altman Z-Score Ratio
for Myomo Inc.

Provide Quick Ratio
for Myomo Inc.

Provide Current Ratio
for Myomo Inc.

Provide Cash Ratio
for Myomo Inc.

What is the historical Revenue growth
over the last 5 years for Myomo Inc?

What is the historical Net Income growth
over the last 5 years for Myomo Inc?

What is the current Free Cash Flow
of Myomo Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Myomo Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Myomo Inc

Current Assets 13.7m
Cash & Short-Term Investments 8.9m
Receivables 2.4m
Other Current Assets 2.4m
Non-Current Assets 930.6k
PP&E 839.4k
Other Non-Current Assets 91.2k
Current Liabilities 5.5m
Accounts Payable 1.1m
Accrued Liabilities 4.3m
Other Current Liabilities 105k
Non-Current Liabilities 115.2k
Other Non-Current Liabilities 115.2k
Efficiency

Earnings Waterfall
Myomo Inc

Revenue
21.1m USD
Cost of Revenue
-6.9m USD
Gross Profit
14.2m USD
Operating Expenses
-23.7m USD
Operating Income
-9.5m USD
Other Expenses
15k USD
Net Income
-9.4m USD

Free Cash Flow Analysis
Myomo Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the second quarter of 2024, Myomo experienced remarkable financial growth, with revenues rising by 77% year-over-year to $7.5 million. This surge was largely due to the inclusion of Medicare Part B patients, who made up 47% of the revenue. The company achieved a record 282 patients in its pipeline, a 22% increase from the previous year. Shipments also grew, with 74 MyoPros delivered. Gross margins maintained a strong 70.8%. Looking forward, Q3 revenue is expected to range between $8.0 and $8.5 million, representing 58-67% year-over-year growth, driven by expanded production capacity and increased advertising.

What is Earnings Call?
Fundamental Scores

MYO Profitability Score
Profitability Due Diligence

Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Exceptional 3-Years Revenue Growth
29/100
Profitability
Score

Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

MYO Solvency Score
Solvency Due Diligence

Myomo Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Myomo Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MYO Price Targets Summary
Myomo Inc

Wall Street analysts forecast MYO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYO is 6.48 USD with a low forecast of 2.27 USD and a high forecast of 8.93 USD.

Lowest
Price Target
2.27 USD
38% Downside
Average
Price Target
6.48 USD
77% Upside
Highest
Price Target
8.93 USD
144% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MYO?

Click here to dive deeper.

Dividends

Myomo Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MYO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MYO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Myomo Inc

Country

United States of America

Industry

Health Care

Market Cap

110.6m USD

Dividend Yield

0%

Description

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

Contact

MASSACHUSETTS
Boston
137 Portland Street, 4th Floor
+16179969058
myomo.com

IPO

2017-06-12

Employees

100

Officers

Chairman, President & CEO
Mr. Paul R. Gudonis
Chief Financial Officer
Mr. David A. Henry
Chief Medical Officer
Dr. Harry Kovelman M.D.
Global Director of Operations
Colin Anderson
Director of Marketing
Mr. Joseph Chicoskie
Senior Director of Human Resources
Ms. Galina Shtivelman
Show More
Chief Commercial Officer
Mr. Micah J. Mitchell
Show Less

See Also

Discover More
What is the Intrinsic Value of one MYO stock?

The intrinsic value of one MYO stock under the Base Case scenario is 3.51 USD.

Is MYO stock undervalued or overvalued?

Compared to the current market price of 3.66 USD, Myomo Inc is Overvalued by 4%.

Back to Top